For the Inventor, By the Inventor

Enter assignee name

Kinki University

Calculating rank

USPTO Granted Patents = 55

% Expired Patents = 36.4

EPO Patents = 29

Trademarks = 2

Forward Citations = 49

Loading Chart...

Loading Chart...

162 inventors (with patents filed for the assignee):

Atsufumi Kawabata (6 out of 8 patents)

Kazuhiko Nakagawa (5 out of 6 patents)

Tamio Ida (4 out of 4 patents)

4. Kimio Yonesaka (4 out of 4 patents)

5. Shunji Ishiwata (3 out of 4 patents)

6. Atsushi Taga (3 out of 4 patents)

7. Hiroyuki Nishikawa (3 out of 8 patents)

8. Osamu Muraoka (3 out of 3 patents)

9. Shigeki Hontsu (3 out of 3 patents)

10. Hiroaki Nishikawa (3 out of 3 patents)

11. Masanobu Kusunoki (3 out of 3 patents)

12. Takeharu Etoh (3 out of 14 patents)

13. Hiroto Tanaka (2 out of 4 patents)

14. Toru Ogawa (2 out of 3 patents)

15. Kenji Hirotani (2 out of 3 patents)

Core Competencies:

Cancer Treatment

Ocular Therapies

Biomarkers

Anticancer Agents

Nanoparticles

Calcium Channel Inhibitors

Biocompatible Materials

Image Sensors

Processed Food

Therapeutic Agents

Biomass Production

Gene Delivery

55 patents: Sort by Forward Citations

1. 12715842 - D-luciferin, D-luciferin derivative, precursor of these compounds and method for producing these compounds (2026-08-25),

2. 12667557 - METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE (2026-06-30),

3. 12636310 - Therapeutic agent for short tear breakup time-type dry eye and eye drops containing same (2026-05-26),

4. 12583938 - Protein biomarker and uses thereof (2026-03-24),

5. 12582369 - Mammography apparatus (2026-03-24),

6. 12338198 - Cancer cell growth inhibiting composition and processed food (2025-06-24),

7. 12102713 - Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease (2024-10-01),

8. 11951231 - Therapeutic agent for intervertebral disc degeneration and material for culturing inter vertebral disc cells (2024-04-09),

9. 11879150 - Treatment selection method and biomarker indicating selection (2024-01-23),

10. 11873344 - Protein biomarker and uses thereof (2024-01-16),

11. 11793845 - Composition for ameliorating peripheral sensory neuropathy (2023-10-24),

12. 11479537 - T-type calcium channel inhibitor (2022-10-25),

13. 11446608 - Method for reducing HTO concentration in aqueous solution (2022-09-20),

14. 11432552 - Deodorizing/antibacterial agent (2022-09-06),

15. 11420944 - Voltage-dependent t-type calcium channel blocker (2022-08-23),

Company Overview

Kinki University, located in Osaka, Japan, is a prominent institution specializing in biotechnology and medicine. The university focuses on advancing research in critical areas such as cancer treatment, ocular therapies, and the development of biomarkers. Its innovative work includes the exploration of anticancer agents, nanoparticles, and calcium channel inhibitors, alongside the creation of biocompatible materials and image sensors. Kinki University is dedicated to fostering advancements that contribute to healthcare and medical technology on a global scale.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

55 Patents

#177 in Osaka

#1,623 in Japan

#12,945 in the World

Kinki University

Forward Citations = 49

162 inventors:

Atsufumi Kawabata (6 out of 8 patents)

Kazuhiko Nakagawa (5 out of 6 patents)

Tamio Ida (4 out of 4 patents)

4. Kimio Yonesaka (4 out of 4 patents)

5. Shunji Ishiwata (3 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kinki University. Retrieved from https://idiyas.com/company/kinki-university

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…